Association of CHAT Gene Polymorphism rs3793790 and rs2177370 with Donepezil Response and the Risk of Alzheimer's Disease Continuum
DOI: https://doi.org/10.2147/cia.s462786
IF: 3.829
2024-06-12
Clinical Interventions in Aging
Abstract:Hongmei Sun, 1, 2 Chao Lv, 2, 3 Xiaoxue Zhang, 1, 2 Xuan Sun, 1, 3, 4 Siyu Chen, 1, 3, 4 Ke Li, 3, 4 Yazhuo Hu, 2, 3 Yuxin Feng, 1, 2 Tong Yin, 2, 3 Jianjun Jia 2, 3 1 Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China; 2 Institute of Geriatrics, Chinese PLA General Hospital, Beijing, People's Republic of China; 3 National Clinical Research Center of Geriatric Diseases, Chinese PLA General Hospital, Beijing, People's Republic of China; 4 Department of Geriatric Neurology, the Second Medical Centre, Chinese PLA General Hospital, Beijing, People's Republic of China Correspondence: Jianjun Jia; Tong Yin, Institute of Geriatrics, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, Haidian District, 100853, People's Republic of China, Email ; Background: Genetic variation plays an important role in drug response, there are few relevant studies on patients with Alzheimer's disease continuum (ADC). Objective: This study focused on the associations between two single nucleotide polymorphisms (SNPs) (rs3793790 and rs2177370) located in the CHAT gene and donepezil response in ADC patients, and further evaluated the associations between the two SNPs and ADC. Material and Methods: According to 2018 National Institute on Aging and Alzheimer's Association (NIA-AA) standard, amyloid β-protein positive (Aβ+) and negative (Aβ-) patients were recruited according to the Aβ-PET/CT standard. rs3793790 and rs2177370 were genotyped in buccal swab samples by using the MassARRAY system. We used the Mini Mental State Examination (MMSE) in Chinese version, caregiver evaluation, and prescribing behavior to assess therapeutic response during the 9-month period. Using logistic regression models, we analyzed the relationship between the two SNPs and donepezil response in 58 Aβ+ patients treated with donepezil alone at the initial diagnosis of ADC. We also explored a probable link between the two SNPs and ADC in 147 Aβ+ and 73 Aβ– patients using a logistic regression analysis. Results: The chance of donepezil response was higher in patients with the G allele of rs3793790 and/or the A allele of rs2177370 than in those without (odds ratio (OR) 6.83, 95% confidence interval (CI): 1.64– 28.49). Additionally, the rs3793790 variant was not associated with ADC, whereas the A allele in rs2177370 increased 1.51-fold the ADC risk (OR 2.51, 95% CI: 1.28– 4.95). Conclusion: The genetic variants of rs3793790 and rs2177370 were associated with the donepezil response, and rs2177370 may have a moderate relationship with the risk of ADC. Keywords: Alzheimer's disease, pharmacogenomics, variant, gene, donepezil Alzheimer's disease (AD), the main type of dementia, is characterized by a progressive deterioration in cognition with varying degrees of psycho-behavioural symptoms, eventually leading to damage in the basic bodily functions. 1 Characteristic pathological changes have occurred in the brain before the patient has clinical symptoms, and amyloid β-protein (Aβ) deposition and hyperphosphorylated tau protein are key links of AD pathogenesis. 2 As pathological changes such as Aβ and tau continue to worsen, the appearance and progression of clinical symptoms are eventually elicited. 3 Therefore, it is considered to be an Alzheimer's disease continuum (ADC) rather than an entity. 3 However, therapeutic options are limited, with two main categories of drugs in clinical practice, including acetylcholinesterase inhibitors (AChEIs) represented by donepezil and N-methyl-D-aspartic acid (NMDA) receptor blockers represented by memantine. 4 In the new era of advocating the concept of precision medicine, the development of pharmacogenomics (PGx) has provided new strategies for ADC treatment and helped optimize treatment using existing drugs. 5 PGx focuses on the action of genetic variation in mediating pharmacokinetics and pharmacodynamics, ultimately achieving improved drug action and reducing adverse effects in clinical practice. 6 Furthermore, a comprehensive insight into the genetic mechanisms of different drug responses can facilitate the development of new drugs. 7 Currently, a multitude of retrospective analyses and prospective trials have been conducted on cardiovascular, oncological, and psychiatric disorders to confirm the hypothesis that pharmacogenomically guided treatment may optimize drug outcomes in clinical practice. However, few relevant studies are available on ADC pharmaco -Abstract Truncated-
geriatrics & gerontology,gerontology